P21 (P021)

What P21 is

The starting point is CNTF, ciliary neurotrophic factor. This is an endogenous protein that keeps nerve cells alive and supports their maturation. As a complete protein, CNTF failed as a medicine: in human studies it caused loss of appetite, muscle pain, gastrointestinal complaints and weight loss, and it barely reaches the brain.

The group led by Khalid Iqbal therefore searched for the smallest piece of CNTF that still works. Using antibodies that neutralize CNTF, they found it in the region of amino acids 147 to 150. A first candidate was called Peptide 6. From this, P021 was developed: 4 amino acids, linked at the end to an adamantane group. This cage-like carbon structure makes the molecule more fat-soluble, protects it from breakdown and helps it cross the blood–brain barrier.

The peptide has nothing to do with the protein p21, a cell cycle inhibitor that plays a role in cancer and aging research. The identical name is a coincidence and regularly causes confusion in searches.

How it is supposed to work

In the hippocampus, the brain’s memory center, new nerve cells form even in adulthood. This neurogenesis declines with age and is disrupted in Alzheimer’s disease. P021 is supposed to act here, via two routes. It inhibits the signal of a related messenger called LIF, which according to the developers favors the maturation of stem cells into nerve cells, and it increases the production of BDNF, one of the most important growth factors for nerve cells and synapses.

More BDNF has a second effect that is particularly interesting for Alzheimer’s research. It slows the enzyme GSK3-beta, which loads the tau protein with excessive phosphate groups. Overloaded tau forms the fiber bundles that destroy nerve cells in Alzheimer’s disease. Overall, the developer group describes P021 as a substance meant to shift the brain from degeneration back toward regeneration.

What it is used for

P021 was developed as a candidate against Alzheimer’s disease and related conditions. It was also tested in models of Down syndrome, traumatic brain injury, a rare genetic epilepsy and a retinal disease. In all cases it was given orally, usually with the feed over weeks to months.

In the nootropics scene, by contrast, P21 is traded as an agent for memory, learning ability and mental freshness in healthy people, sometimes also as a longevity building block against brain decline in old age. This use has little to do with the studies: the animals were sick or old, and what was measured was whether deficits were compensated, not whether healthy brains got better.

What the studies show

Alzheimer’s mice, 12 months, 2014

Kazim and colleagues fed triple-transgenic Alzheimer’s mice with P021 for 12 months, starting at a moderate disease stage. The overloading of tau with phosphate groups decreased markedly, soluble beta-amyloid fell, and the plaques showed only a trend. Memory, neurogenesis and synaptic plasticity improved. As the mechanism, the authors found more BDNF and lower activity of GSK3-beta.

Old rats, 2014

Bolognin and colleagues gave rats aged 22 to 24 months P021 with their feed over an extended period. The age-related decline in learning and memory was smaller, neurogenesis was preserved, BDNF rose, and synapses in the cortex and hippocampus recovered. In magnetic resonance spectroscopy, a marker that is elevated in old animals fell. This is the study that comes closest to the nootropics narrative, and it is an animal experiment.

A negative finding, 2024

Mottolese and colleagues tested P021 in a rare genetic brain disorder, CDKL5 deficiency. In human nerve cells in the culture dish it worked and corrected defects in growth and maturation. In mice with the same gene defect, by contrast, BDNF did not rise under chronic administration, the changes in the brain remained, and the behavioral benefit was limited. The finding shows that P021 does not work reliably in every model.

Where the data stop

The gap is fundamental: there is not a single study in humans, neither on efficacy nor on tolerability, and no entry can be found in the ClinicalTrials.gov registry. Pharmacokinetics and safety are known only from animals. Whether P021 reaches the brain in humans, how long it acts and in what amount it would be tolerated, nobody knows.

Then there is the origin of the data. Almost all studies come from the research group that developed P021; even the one study with a negative result has Iqbal as a co-author. That does not speak against the quality, but independent confirmation is missing. And the animals were sick or old. Whether a healthy brain benefits from more neurogenesis is a completely different question that nobody has studied.

Status, approval and legal

P021 is not approved as a medicine anywhere and is at the preclinical stage. It is offered on the gray market as a research peptide; usage and dosage information is omitted here. The 2026 Prohibited List of the World Anti-Doping Agency does not name P021 explicitly. As a pharmacologically active substance without approval, however, it falls under class S0, which is prohibited at all times.

Safety

P021 has not been studied in humans, so no safety profile exists. The animal data on tolerability come from the developer group itself. The parent protein CNTF led to loss of appetite, muscle pain, gastrointestinal complaints and weight loss in human studies. Whether the small fragment has similar effects is unknown. P021 intervenes in growth factor signals and the formation of new cells in the brain; the consequences of long-term use in healthy people are unknown. There are no data for pregnancy, breastfeeding or people with tumor diseases. Gray-market products are unverified in identity, purity and content.

Sources

• Baazaoui N, Iqbal K, Biomolecules 2022 — review of P021 by the developer group
• Kazim SF et al., Neurobiology of Disease 2014 — 12 months of P021 in Alzheimer’s mice
• Bolognin S et al., Neurobiology of Aging 2014 — P021 against age-related memory decline in rats
• Kazim SF et al., Scientific Reports 2017 — Down syndrome mouse model
• Kazim SF, Iqbal K, Molecular Neurodegeneration 2016 — review of neurotrophic factor mimetics
• Chohan MO et al., Neurosurgery 2015 — precursor Peptide 6 after traumatic brain injury
• Mottolese N et al., Journal of Neurodevelopmental Disorders 2024 — CDKL5 model, no BDNF increase in animals
• ClinicalTrials.gov — search for P021, no study entry
• WADA Prohibited List 2026, officially published in the Austrian Federal Law Gazette III No. 219/2025